Skip to main content

Table 3 NF-κB staining and ovarian tumor survival outcomes, the VUMC TROC

From: Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

  Progression-free survival (PFS) Overall survival (OS)
Unadjusted Adjusted a Unadjusted Adjusted a
Compartmentalized staining HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
p52: Non-canonical NF-κB transcription factor
 Cytoplasmic staining 2.15 (1.55–2.98) < 0.001 1.54 (1.09–2.18) 0.015 1.98 (1.42–2.75) < 0.001 1.53 (1.07–2.18) 0.019
 Nuclear staining 2.05 (1.46–2.86) < 0.001 1.67 (1.15–2.42) 0.006 1.82 (1.30–2.55) < 0.001 1.49 (1.02–2.17) 0.041
p65: Canonical NF-κB transcription factor
 Cytoplasmic staining 1.02 (0.75–1.40) 0.885 1.05 (0.75–1.47) 0.776 1.08 (0.79–1.48) 0.636 1.13 (0.81–1.57) 0.472
 Nuclear staining 1.40 (1.02–1.92) 0.037 1.20 (0.85–1.69) 0.300 1.37 (1.00–1.89) 0.052 1.31 (0.93–1.84) 0.124
Total staining
Independent models
  p52: Cytoplasmic or Nuclear 1.78 (1.28–2.47) < 0.001 1.53 (1.08–2.19) 0.018 1.73 (1.24–2.41) 0.001 1.61 (1.12–2.33) 0.011
  p65: Cytoplasmic or Nuclear 1.38 (0.99–1.92) 0.054 1.27 (0.89–1.81) 0.186 1.38 (0.99–1.92) 0.059 1.31 (0.92–1.88) 0.138
Mutually adjusted models b
  p52: Cytoplasmic or Nuclear 1.70 (1.21–2.38) 0.002 1.49 (1.04–2.14) 0.030 1.64 (1.16–2.32) 0.005 1.57 (1.08–2.27) 0.018
  p65: Cytoplasmic or Nuclear 1.24 (0.88–1.73) 0.217 1.18 (0.82–1.71) 0.348 1.22 (0.86–1.72) 0.260 1.23 (0.85–1.77) 0.265
Among high-grade serous cases c
Independent models
  p52: Cytoplasmic or Nuclear 1.79 (1.17–2.75) 0.007 1.68 (1.08–2.62) 0.020 1.65 (1.07–2.56) 0.024 1.61 (1.03–2.53) 0.038
  p65: Cytoplasmic or Nuclear 0.90 (0.58–1.36) 0.606 1.14 (0.74–1.76) 0.551 1.02 (0.67–1.57) 0.921 1.16 (0.75–1.81) 0.499
Mutually adjusted models b
  p52: Cytoplasmic or Nuclear 1.91 (1.23–2.96) 0.004 1.68 (1.07–2.62) 0.024 1.70 (1.09–2.66) 0.021 1.59 (1.01–2.52) 0.045
  p65: Cytoplasmic or Nuclear 0.76 (0.49–1.18) 0.223 1.03 (0.66–1.61) 0.899 0.89 (0.57–1.39) 0.612 1.09 (0.69–1.69) 0.719
  1. a Adjusted for age at diagnosis (continuous), stage (early, late), histologic subtype (serous, endometrioid and clear cell, mucinous and other), grade (borderline, low, high), and platinum and/or taxane chemotherapy (yes, no or unknown)
  2. b Mutually adjusted models include both p52 and p65 (cytoplasmic or nuclear staining)
  3. c Model does not include adjustment for grade or histologic subtype because only high-grade serous cases (N = 118) were included in this analysis
\